Universal Beteiligungs und Servicegesellschaft mbH Takes Position in Xencor, Inc. (NASDAQ:XNCR)

Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in Xencor, Inc. (NASDAQ:XNCR) during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 12,733 shares of the biopharmaceutical company’s stock, valued at approximately $135,000.

A number of other institutional investors have also modified their holdings of XNCR. American Century Companies Inc. raised its stake in Xencor by 11.1% during the fourth quarter. American Century Companies Inc. now owns 114,231 shares of the biopharmaceutical company’s stock worth $2,625,000 after acquiring an additional 11,396 shares during the period. LPL Financial LLC raised its stake in Xencor by 12.0% during the fourth quarter. LPL Financial LLC now owns 19,680 shares of the biopharmaceutical company’s stock worth $452,000 after acquiring an additional 2,113 shares during the period. Norges Bank acquired a new stake in Xencor during the fourth quarter worth about $3,397,000. Pictet Asset Management Holding SA acquired a new stake in Xencor during the fourth quarter worth about $247,000. Finally, Wellington Management Group LLP acquired a new stake in Xencor during the fourth quarter worth about $632,000.

Insider Activity

In related news, Director Ellen Feigal sold 2,993 shares of the firm’s stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $9.22, for a total transaction of $27,595.46. Following the completion of the sale, the director directly owned 19,183 shares in the company, valued at approximately $176,867.26. This trade represents a 13.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Kurt A. Gustafson sold 2,993 shares of the firm’s stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $9.22, for a total transaction of $27,595.46. Following the sale, the director owned 20,183 shares of the company’s stock, valued at $186,087.26. The trade was a 12.91% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 11,194 shares of company stock worth $103,209 over the last three months. Corporate insiders own 5.23% of the company’s stock.

Xencor Stock Performance

Xencor stock opened at $7.95 on Wednesday. The firm has a 50 day simple moving average of $8.69 and a 200-day simple moving average of $11.20. The company has a debt-to-equity ratio of 0.16, a current ratio of 5.89 and a quick ratio of 5.89. The stock has a market capitalization of $565.80 million, a PE ratio of -2.60 and a beta of 0.89. Xencor, Inc. has a 12-month low of $7.16 and a 12-month high of $27.24.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.06). The company had revenue of $32.73 million during the quarter, compared to the consensus estimate of $23.44 million. Xencor had a negative net margin of 181.17% and a negative return on equity of 31.94%. The company’s revenue was up 104.6% on a year-over-year basis. During the same quarter last year, the business earned ($1.11) earnings per share. As a group, equities research analysts expect that Xencor, Inc. will post -3.68 EPS for the current fiscal year.

Wall Street Analyst Weigh In

XNCR has been the topic of several research reports. Barclays dropped their price objective on shares of Xencor from $22.00 to $6.00 and set an “underweight” rating on the stock in a research note on Thursday, May 8th. Wedbush reiterated an “outperform” rating and set a $31.00 price objective on shares of Xencor in a research note on Wednesday, April 30th. Finally, William Blair started coverage on Xencor in a research report on Monday, April 21st. They set an “outperform” rating for the company. Two analysts have rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, Xencor currently has an average rating of “Moderate Buy” and a consensus price target of $28.00.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.